Symbols / BNR Stock $20.69 +0.49% Burning Rock Biotech Limited

Healthcare • Diagnostics & Research • China • NGM
BNR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Yusheng Han
Exch · Country NGM · China
Market Cap 222.76M
Enterprise Value 1.73B
Income -55.35M
Sales 539.57M
FCF (ttm) -41.70M
Book/sh 7.49
Cash/sh 4.57
Employees —
Insider 10d —
IPO Jun 12, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -35.67
PEG —
P/S 0.41
P/B 2.76
P/C —
EV/EBITDA -500.98
EV/Sales 3.21
Quick Ratio 2.67
Current Ratio 2.99
Debt/Eq 8.06
LT Debt/Eq —
EPS (ttm) -0.75
EPS next Y -0.58
EPS Growth —
Revenue Growth 0.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-05-30
Earnings (prior) 2023-05-30
ROA -4.02%
ROE -9.92%
ROIC —
Gross Margin 74.67%
Oper. Margin -9.53%
Profit Margin -10.26%
Shs Outstand 9.03M
Shs Float 44.05M
Insider Own 3.92%
Instit Own 44.71%
Short Float —
Short Ratio 1.41
Short Interest 63.95K
52W High 41.72
vs 52W High -50.41%
52W Low 2.18
vs 52W Low 849.08%
Beta 1.60
Impl. Vol. —
Rel Volume 0.67
Avg Volume 25.28K
Volume 16.88K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $20.59
Price $20.69
Change 0.49%
About

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$20.69
Latest analyst target
3. DCF / Fair value
$-83.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$20.69
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2021-07-14 init CICC — → Outperform $40
2020-07-13 init B of A Securities — → Buy $32
2020-07-07 init Cowen & Co. — → Outperform —
News
RSS: Latest BNR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 HAN YUSHENG Director — 314,870 $17.36 $5,466,143
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
515.82
-4.02%
537.43
-4.58%
563.24
+10.90%
507.86
Operating Revenue
515.82
-4.02%
537.43
-4.58%
563.24
+10.90%
507.86
Cost Of Revenue
153.42
-11.93%
174.21
-4.91%
183.20
+27.47%
143.72
Reconciled Cost Of Revenue
153.42
-11.93%
174.21
-4.91%
183.20
+27.47%
143.72
Gross Profit
362.40
-0.23%
363.23
-4.42%
380.04
+4.36%
364.15
Operating Expense
684.83
-33.68%
1,032.55
-24.10%
1,360.45
+17.16%
1,161.21
Research And Development
232.29
-33.06%
347.02
-17.74%
421.87
+14.68%
367.86
Selling General And Administration
452.54
-33.99%
685.53
-26.96%
938.58
+18.31%
793.35
Selling And Marketing Expense
190.90
-22.93%
247.71
-33.10%
370.29
+22.17%
303.10
General And Administrative Expense
261.64
-40.24%
437.82
-22.96%
568.28
+15.92%
490.26
Other Gand A
261.64
-40.24%
437.82
-22.96%
568.28
+15.92%
490.26
Total Expenses
838.25
-30.54%
1,206.76
-21.82%
1,543.64
+18.29%
1,304.93
Operating Income
-322.43
+51.83%
-669.32
+31.73%
-980.41
-23.00%
-797.06
Total Operating Income As Reported
-357.56
+46.58%
-669.32
+31.73%
-980.41
-23.00%
-797.06
EBITDA
-270.23
+49.58%
-535.92
+37.42%
-856.31
-14.71%
-746.50
Normalized EBITDA
-235.00
+56.11%
-535.50
+37.58%
-857.86
-15.05%
-745.64
Reconciled Depreciation
52.20
-60.87%
133.40
+7.50%
124.10
+159.80%
47.77
EBIT
-322.43
+51.83%
-669.32
+31.73%
-980.41
-23.44%
-794.26
Total Unusual Items
-35.23
-8287.38%
-0.42
-127.11%
1.55
+281.38%
-0.85
Total Unusual Items Excluding Goodwill
-35.23
-8287.38%
-0.42
-127.11%
1.55
+281.38%
-0.85
Special Income Charges
-35.13
0.00
0.00
—
Impairment Of Capital Assets
35.13
0.00
0.00
—
Net Income
-346.63
+46.97%
-653.69
+32.69%
-971.23
-21.91%
-796.70
Pretax Income
-340.74
+47.68%
-651.30
+32.80%
-969.25
-21.80%
-795.80
Net Non Operating Interest Income Expense
12.21
-31.99%
17.96
+89.85%
9.46
+392.35%
1.92
Interest Expense Non Operating
—
0.00
—
1.54
Net Interest Income
12.21
-31.99%
17.96
+89.85%
9.46
+392.35%
1.92
Interest Expense
—
0.00
—
1.54
Interest Income Non Operating
12.21
-31.99%
17.96
+89.85%
9.46
+173.59%
3.46
Interest Income
12.21
-31.99%
17.96
+89.85%
9.46
+173.59%
3.46
Other Income Expense
-30.52
-47789.06%
0.06
-96.24%
1.70
+359.69%
-0.66
Other Non Operating Income Expenses
4.71
+872.31%
0.48
+218.42%
0.15
-23.62%
0.20
Gain On Sale Of Security
-0.10
+76.19%
-0.42
-127.11%
1.55
+281.38%
-0.85
Tax Provision
5.88
+146.44%
2.39
+20.30%
1.99
+120.80%
0.90
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-8.81
-8287.38%
-0.10
-127.11%
0.39
+281.38%
-0.21
Net Income Including Noncontrolling Interests
-346.63
+46.97%
-653.69
+32.69%
-971.23
-21.91%
-796.70
Net Income From Continuing Operation Net Minority Interest
-346.63
+46.97%
-653.69
+32.69%
-971.23
-21.91%
-796.70
Net Income From Continuing And Discontinued Operation
-346.63
+46.97%
-653.69
+32.69%
-971.23
-21.91%
-796.70
Net Income Continuous Operations
-346.63
+46.97%
-653.69
+32.69%
-971.23
-21.91%
-796.70
Normalized Income
-320.21
+50.99%
-653.37
+32.81%
-972.39
-22.15%
-796.06
Net Income Common Stockholders
-346.63
+46.97%
-653.69
+32.69%
-971.23
-21.91%
-796.70
Otherunder Preferred Stock Dividend
—
—
0.00
0.00
Diluted EPS
-33.70
+47.18%
-63.80
+31.76%
-93.50
-22.22%
-76.50
Basic EPS
-33.70
+47.18%
-63.80
+31.76%
-93.50
-22.22%
-76.50
Basic Average Shares
10.29
+0.53%
10.24
-1.46%
10.39
-0.29%
10.42
Diluted Average Shares
10.29
+0.53%
10.24
-1.46%
10.39
-0.29%
10.42
Diluted NI Availto Com Stockholders
-346.63
+46.97%
-653.69
+32.69%
-971.23
-21.91%
-796.70
Line Item Trend 2024-12-31 2023-12-31 2022-12-31
Total Assets
885.30
-14.87%
1,040.00
-34.49%
1,587.47
Current Assets
776.62
-12.16%
884.10
-29.76%
1,258.76
Cash Cash Equivalents And Short Term Investments
519.85
-15.48%
615.10
-32.07%
905.45
Cash And Cash Equivalents
519.85
-15.48%
615.10
-32.07%
905.45
Other Short Term Investments
—
—
0.00
Receivables
173.45
+3.36%
167.81
-1.42%
170.23
Accounts Receivable
152.01
+19.83%
126.86
+15.37%
109.95
Gross Accounts Receivable
197.88
+19.74%
165.25
+8.10%
152.87
Allowance For Doubtful Accounts Receivable
-45.87
-19.46%
-38.40
+10.53%
-42.91
Other Receivables
13.86
-39.09%
22.75
-45.52%
41.76
Taxes Receivable
7.40
-56.53%
17.03
-7.54%
18.42
Accrued Interest Receivable
0.18
-84.99%
1.18
+1044.66%
0.10
Loans Receivable
—
—
0.00
Inventory
53.76
-22.11%
69.02
-47.04%
130.32
Raw Materials
32.83
-23.13%
42.70
-51.16%
87.43
Work In Process
6.62
+25.85%
5.26
-30.69%
7.59
Finished Goods
14.32
-32.01%
21.06
-40.35%
35.31
Prepaid Assets
17.99
-38.50%
29.25
+29.33%
22.62
Current Deferred Assets
8.86
0.00
—
Restricted Cash
2.31
+1827.50%
0.12
-99.39%
19.82
Other Current Assets
0.40
-85.88%
2.80
-72.90%
10.33
Total Non Current Assets
108.69
-30.29%
155.91
-52.57%
328.70
Net PPE
100.34
-30.41%
144.20
-51.94%
300.03
Gross PPE
581.71
+6.10%
548.29
-5.03%
577.33
Accumulated Depreciation
-481.37
-19.12%
-404.10
-45.73%
-277.30
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
288.46
-2.42%
295.63
+2.89%
287.31
Construction In Progress
0.63
+15.69%
0.55
-79.39%
2.66
Other Properties
105.39
+62.83%
64.73
-35.26%
99.98
Leases
187.22
-0.09%
187.39
+0.01%
187.38
Goodwill And Other Intangible Assets
0.42
-56.33%
0.96
-51.46%
1.99
Other Intangible Assets
0.42
-56.33%
0.96
-51.46%
1.99
Investments And Advances
0.00
-100.00%
0.34
-51.16%
0.69
Long Term Equity Investment
0.00
-100.00%
0.34
-51.16%
0.69
Other Non Current Assets
7.93
+55.78%
5.09
-75.64%
20.89
Total Liabilities Net Minority Interest
304.48
+12.11%
271.59
-36.71%
429.13
Current Liabilities
266.30
+1.11%
263.36
-35.99%
411.45
Payables And Accrued Expenses
105.14
+1.05%
104.05
-37.39%
166.20
Payables
48.20
+24.63%
38.68
-37.58%
61.97
Accounts Payable
33.75
+86.85%
18.06
-64.55%
50.95
Current Accrued Expenses
56.94
-12.90%
65.37
-37.28%
104.23
Pensionand Other Post Retirement Benefit Plans Current
—
0.00
-100.00%
38.97
Total Tax Payable
14.46
-29.88%
20.62
+87.02%
11.03
Current Debt And Capital Lease Obligation
24.57
+184.54%
8.63
-76.81%
37.24
Current Debt
—
—
—
Other Current Borrowings
—
—
—
Current Capital Lease Obligation
24.57
+184.54%
8.63
-76.81%
37.24
Current Deferred Liabilities
118.49
-10.06%
131.73
-11.85%
149.44
Current Deferred Revenue
118.49
-10.06%
131.73
-11.85%
149.44
Other Current Liabilities
18.10
-4.46%
18.95
-3.38%
19.61
Total Non Current Liabilities Net Minority Interest
38.18
+364.07%
8.23
-53.45%
17.68
Long Term Debt And Capital Lease Obligation
27.75
+652.14%
3.69
-72.77%
13.55
Long Term Capital Lease Obligation
27.75
+652.14%
3.69
-72.77%
13.55
Non Current Deferred Liabilities
—
—
—
Non Current Deferred Revenue
—
—
—
Other Non Current Liabilities
10.43
+129.78%
4.54
+10.01%
4.12
Stockholders Equity
580.83
-24.41%
768.41
-33.66%
1,158.34
Common Stock Equity
580.83
-24.41%
768.41
-33.66%
1,158.34
Capital Stock
0.14
+5.84%
0.14
-0.72%
0.14
Common Stock
0.14
+5.84%
0.14
-0.72%
0.14
Share Issued
110.64
+4.91%
105.46
-0.19%
105.67
Ordinary Shares Number
107.61
+5.05%
102.44
-0.20%
102.64
Treasury Shares Number
3.02
+0.00%
3.02
+0.00%
3.02
Additional Paid In Capital
5,002.26
+3.15%
4,849.34
+5.82%
4,582.79
Retained Earnings
-4,200.26
-8.99%
-3,853.64
-20.43%
-3,199.95
Gains Losses Not Affecting Retained Earnings
-158.05
+2.16%
-161.53
+2.53%
-165.72
Treasury Stock
63.26
-3.99%
65.90
+11.84%
58.92
Other Equity Adjustments
-158.05
+2.16%
-161.53
+2.53%
-165.72
Total Equity Gross Minority Interest
580.83
-24.41%
768.41
-33.66%
1,158.34
Total Capitalization
580.83
-24.41%
768.41
-33.66%
1,158.34
Working Capital
510.32
-17.79%
620.73
-26.74%
847.31
Invested Capital
580.83
-24.41%
768.41
-33.66%
1,158.34
Total Debt
52.32
+324.55%
12.32
-75.73%
50.79
Capital Lease Obligations
52.32
+324.55%
12.32
-75.73%
50.79
Net Tangible Assets
580.41
-24.37%
767.45
-33.63%
1,156.36
Tangible Book Value
580.41
-24.37%
767.45
-33.63%
1,156.36
Duefrom Related Parties Current
—
—
—
Interest Payable
—
—
0.00
Non Current Note Receivables
0.00
-100.00%
5.32
+4.21%
5.11
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-92.26
+63.93%
-255.78
+44.01%
-456.81
+4.41%
-477.89
Cash Flow From Continuing Operating Activities
-92.26
+63.93%
-255.78
+44.01%
-456.81
+4.41%
-477.89
Net Income From Continuing Operations
-346.63
+46.97%
-653.69
+32.69%
-971.23
-21.91%
-796.70
Depreciation Amortization Depletion
52.20
-60.87%
133.40
+7.50%
124.10
+159.80%
47.77
Depreciation
51.39
-60.91%
131.45
+8.87%
120.75
—
Amortization Cash Flow
0.81
-58.26%
1.95
-41.83%
3.35
—
Depreciation And Amortization
52.20
-60.87%
133.40
+7.50%
124.10
+159.80%
47.77
Amortization Of Intangibles
0.81
-58.26%
1.95
-41.83%
3.35
—
Other Non Cash Items
26.35
-25.12%
35.18
-4.84%
36.97
+3.82%
35.61
Stock Based Compensation
155.62
-40.31%
260.72
-20.22%
326.78
+15.70%
282.43
Provisionand Write Offof Assets
13.74
-29.91%
19.61
-45.72%
36.12
+145.17%
14.73
Asset Impairment Charge
35.37
0.00
0.00
—
Operating Gains Losses
2.29
+67.49%
1.37
-20.04%
1.71
+159.00%
0.66
Unrealized Gain Loss On Investment Securities
5.32
+2574.42%
-0.21
-104.76%
-0.10
0.00
Gain Loss On Sale Of PPE
2.20
+118.25%
1.01
-28.91%
1.42
+696.63%
0.18
Change In Working Capital
-36.53
+29.96%
-52.16
-367.40%
-11.16
+82.12%
-62.40
Change In Receivables
-26.80
-63.44%
-16.40
+61.11%
-42.16
+14.92%
-49.56
Changes In Account Receivables
-32.63
-163.41%
-12.39
+42.40%
-21.50
-13.60%
-18.93
Change In Inventory
2.51
-95.62%
57.28
+364.51%
-21.65
+67.68%
-67.00
Change In Prepaid Assets
19.28
+56.09%
12.35
-63.58%
33.92
+197.30%
-34.86
Change In Payables And Accrued Expense
10.20
+120.26%
-50.37
-200.15%
50.29
+28.49%
39.14
Change In Accrued Expense
-8.69
+54.86%
-19.25
-157.18%
33.66
-23.92%
44.24
Change In Payable
18.89
+160.70%
-31.12
-287.13%
16.63
+425.99%
-5.10
Change In Account Payable
18.89
+160.70%
-31.12
-287.13%
16.63
+425.99%
-5.10
Change In Other Working Capital
-14.11
+18.33%
-17.27
-376.13%
6.26
-90.81%
68.06
Change In Other Current Liabilities
-27.62
+26.83%
-37.74
+0.18%
-37.81
-107.97%
-18.18
Investing Cash Flow
-4.41
+52.56%
-9.30
-24.61%
-7.46
-109.13%
81.70
Cash Flow From Continuing Investing Activities
-4.41
+52.56%
-9.30
-24.61%
-7.46
-109.13%
81.70
Net PPE Purchase And Sale
-3.85
+51.95%
-8.02
+88.18%
-67.88
+67.73%
-210.35
Purchase Of PPE
-5.42
+33.13%
-8.10
+88.47%
-70.29
+66.67%
-210.92
Sale Of PPE
1.56
+1763.10%
0.08
-96.52%
2.41
+327.26%
0.56
Capital Expenditure
-5.98
+36.31%
-9.38
+86.68%
-70.47
+66.98%
-213.45
Net Investment Purchase And Sale
0.00
0.00
-100.00%
65.60
-77.73%
294.58
Purchase Of Investment
—
0.00
0.00
+100.00%
-63.92
Sale Of Investment
0.00
0.00
-100.00%
65.60
-81.70%
358.50
Net Intangibles Purchase And Sale
-0.56
+56.41%
-1.28
-591.89%
-0.18
+92.68%
-2.53
Purchase Of Intangibles
-0.56
+56.41%
-1.28
-591.89%
-0.18
+92.68%
-2.53
Net Other Investing Changes
—
—
-5.00
—
Financing Cash Flow
-0.07
+99.85%
-48.83
+43.38%
-86.24
-63.03%
-52.90
Cash Flow From Continuing Financing Activities
-0.07
+99.85%
-48.83
+43.38%
-86.24
-63.03%
-52.90
Net Issuance Payments Of Debt
0.00
0.00
+100.00%
-2.37
+94.71%
-44.81
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
0.00
0.00
+100.00%
-2.37
+94.71%
-44.81
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
—
0.00
0.00
+100.00%
-39.81
Net Long Term Debt Issuance
—
0.00
0.00
+100.00%
-39.81
Short Term Debt Issuance
—
—
0.00
0.00
Short Term Debt Payments
0.00
0.00
+100.00%
-2.37
+52.60%
-5.00
Net Short Term Debt Issuance
0.00
0.00
+100.00%
-2.37
+52.60%
-5.00
Net Common Stock Issuance
-0.07
+98.97%
-6.98
+90.29%
-71.83
-1582.30%
-4.27
Common Stock Payments
-0.07
+98.97%
-6.98
+90.29%
-71.83
-1582.30%
-4.27
Repurchase Of Capital Stock
-0.07
+98.97%
-6.98
+90.29%
-71.83
-1582.30%
-4.27
Proceeds From Stock Option Exercised
0.00
+100.00%
-41.85
-247.78%
-12.04
-214.81%
-3.82
Net Other Financing Charges
—
—
-12.04
-214.81%
-3.82
Changes In Cash
-96.75
+69.18%
-313.92
+42.98%
-550.51
-22.58%
-449.09
Effect Of Exchange Rate Changes
3.69
-4.45%
3.86
-89.46%
36.67
+199.08%
-37.01
Beginning Cash Position
615.22
-33.51%
925.27
-35.71%
1,439.11
-25.25%
1,925.21
End Cash Position
522.16
-15.13%
615.22
-33.51%
925.27
-35.71%
1,439.11
Free Cash Flow
-98.24
+62.95%
-265.17
+49.71%
-527.28
+23.73%
-691.33
Interest Paid Supplemental Data
0.00
0.00
-100.00%
0.88
-42.19%
1.52
Income Tax Paid Supplemental Data
0.00
0.00
-100.00%
0.10
-91.13%
1.10
Common Stock Issuance
—
—
0.00
0.00
Earnings Losses From Equity Investments
0.09
-74.24%
0.36
+22.79%
0.29
-39.13%
0.48
Issuance Of Capital Stock
—
—
0.00
0.00
Net Preferred Stock Issuance
—
—
0.00
0.00
Preferred Stock Issuance
—
—
0.00
0.00
Preferred Stock Payments
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category